Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States... Show more
The 10-day moving average for NBIX crossed bearishly below the 50-day moving average on October 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 29, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on September 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
NBIX moved below its 50-day moving average on October 10, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 282 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.051) is normal, around the industry mean (17.643). P/E Ratio (40.586) is within average values for comparable stocks, (72.868). Projected Growth (PEG Ratio) (0.360) is also within normal values, averaging (2.089). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (5.612) is also within normal values, averaging (48.567).
a product based biopharmaceutical company
Industry PharmaceuticalsGeneric
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
SOFX | 41.89 | 2.01 | +5.03% |
Defiance Daily Target 2X Long SOFI ETF | |||
NPFI | 26.30 | 0.01 | +0.04% |
Nuveen Preferred and Income ETF | |||
JPI | 20.68 | N/A | N/A |
Nuveen Preferred Securities & Income Opportunities Fund | |||
ARVR | 50.47 | N/A | N/A |
First Trust Indxx Metaverse ETF | |||
FENY | 23.99 | -0.04 | -0.17% |
Fidelity MSCI Energy ETF |
A.I.dvisor tells us that NBIX and ELAN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and ELAN's prices will move in lockstep.
Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
---|---|---|---|---|
NBIX | 100% | -0.12% | ||
ELAN - NBIX | 33% Poorly correlated | +0.90% | ||
LFCR - NBIX | 32% Poorly correlated | -0.91% | ||
CGC - NBIX | 30% Poorly correlated | -0.73% | ||
AMRX - NBIX | 30% Poorly correlated | -0.31% | ||
AQST - NBIX | 29% Poorly correlated | +3.30% | ||
More |
Ticker / NAME | Correlation To NBIX | 1D Price Change % |
---|---|---|
NBIX | 100% | -0.12% |
Pharmaceuticals: Generic industry (221 stocks) | 48% Loosely correlated | +1.43% |